Overview
- Kyrgios tested positive for benzoilecgonine, a cocaine metabolite, after an anti‑doping control at the ATP 250 in Mallorca on June 22, 2026.
- The International Tennis Integrity Agency concluded his use took place in a social setting in Magaluf and that laboratory analysis was consistent with out‑of‑competition use.
- ITIA reduced the sanction to a one‑month suspension conditional on completing an approved treatment programme and Kyrgios accepted the decision without appeal.
- His provisional suspension began on August 4 and ended this week with eligibility to play restored on September 3–4, 2026, but he forfeited Mallorca prize money and ranking points and has fallen to about 918–919 in the ATP list.
- The case shows how context, expert testing and cooperation can sharply lower penalties under WADA rules and it leaves Kyrgios facing reputational damage and questions about sponsors and his short‑term playing prospects.